Jake Scott is an Infectious Disease physician affiliated with Stanford Medicine. OpenAlex indexes 50 publications with 1,829 citations (h-index 17); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Plastic Bronchitis and Protein Losing Enteropathy in Children With Single Ventricle Physiology
Sponsor: Medical College of Wisconsin
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
1 company with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
94.8%Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor16.6%Descovy100%Part D<11 patientsHuman Immunodeficiency Virus Integrase Strand Transfer Inhibitor15.9%Tivicay100%Part D<11 patients+ 9 more classes in this area
Sensory organs
5.2%Fluoroquinolone Antibacterial5.2%Ciprofloxacin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Metformin on the Presence of COVID-19 Symptoms 6 Months After Infection: The ACTIV-6 Randomized Clinical Trial
Clinical Infectious Diseases
2026 - Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025–2026
New England Journal of Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Ranjana Advani, MD
Stanford Medicine
Michael Weisman, MD
Stanford Medicine
Maurice Ohayon, MD, DSC, PhD
Stanford Medicine
Bruno Medeiros, MD
Stanford Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”